Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma (NASDAQ: LUMO) is set to host a key opinion leader webinar on LUM-201 for treating pediatric growth hormone deficiency on April 27, 2021, at 10:30 AM ET. The event will feature presentations from renowned experts Dr. Bradley S. Miller and Dr. Fernando Cassorla, discussing available treatments and unmet needs in PGHD. LUM-201 is a promising oral therapy aiming to increase GH secretion while reducing the need for injections. A corporate update will also be presented, showcasing its clinical program.
Lumos Pharma (NASDAQ: LUMO) announced enhanced results for LUM-201 in treating pediatric growth hormone deficiency (PGHD) at the ENDO 2021 conference.
The data revealed that LUM-201 elicited a significant peak growth hormone (GH) response of 15.0 ng/mL in children, outperforming standard GH secretagogues, which achieved 5.4 ng/mL. Notably, this study involved 68 prepubertal children, indicating LUM-201's therapeutic potential for about 60% of the PGHD population. LUM-201's promising results support its continued development as an alternative to daily injections.
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO) announces participation in several virtual investor conferences in March 2021. Highlights include:
- H.C. Wainwright Global Life Sciences Conference on March 10, 2021 with a pre-recorded presentation.
- Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 with a live presentation and one-on-one meetings.
- 33rd Annual Roth Conference on March 15-17, 2021 featuring presentations and meetings.
Lumos Pharma focuses on developing therapeutics for rare diseases and is evaluating LUM-201 for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. (NASDAQ:LUMO) reported financial results for 2020, highlighting significant achievements including the completion of a merger and the receipt of $26 million from a PRV sale.
They initiated the Phase 2b OraGrowtH210 Trial for LUM-201 targeting pediatric growth hormone deficiency (PGHD). Key insights from studies published in the Journal of Endocrine Society show predictive enrichment markers for patient enrollment in clinical trials. The company anticipates a net loss of $5.7 million for 2020, a decrease from $9.7 million in 2019, with ongoing plans for research and development.
Lumos Pharma has announced the publication of analyses supporting the use of Predictive Enrichment Markers (PEMs) in its ongoing Phase 2b OraGrowtH210 Trial for treating Pediatric Growth Hormone Deficiency (PGHD). Data from previous studies identified two PEMs: a baseline IGF-1 level > 30 ng/ml and peak GH level ≥ 5 ng/mL. The findings indicate that about 60% of diagnosed children with GHD meet PEM criteria, suggesting a targeted patient population for LUM-201 treatment. The company aims to establish an oral alternative to current injection therapies.
Lumos Pharma (NASDAQ:LUMO) will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting from March 20-23, 2021. The presentation titled LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency will be held on March 20, 2021, at 11:00AM ET. LUM-201 is a promising oral therapy for Pediatric Growth Hormone Deficiency, currently undergoing a Phase 2b clinical trial.
Lumos Pharma (NASDAQ:LUMO) will report its full year 2020 financial results on March 9, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. Investors can access the live audio via a provided link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 under evaluation for Pediatric Growth Hormone Deficiency in a Phase 2b trial. The company has received Orphan Drug Designation for LUM-201 in both the US and EU.
Lumos Pharma has appointed An van Es-Johansson, M.D., to its Board of Directors, effective immediately. With over 30 years of experience in rare diseases and clinical development, she will bring valuable expertise as Lumos focuses on its Phase 2b trial for the treatment of pediatric growth hormone deficiency. Dr. van Es-Johansson succeeds Emmett Cunningham, who is resigning to concentrate on his role at Blackstone Life Sciences. The leadership change is expected to enhance Lumos Pharma’s strategic direction and clinical programs.
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The company's presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET, through the conference portal and Lumos Pharma's website. No one-on-one meetings will be conducted during this event. Lumos Pharma focuses on therapeutics for rare diseases, with LUM-201 as its lead candidate for Pediatric Growth Hormone Deficiency.
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, announced its participation in virtual investor conferences in December 2020. The company will engage in a fireside chat on November 23 and host one-on-one meetings on December 2 at the Piper Sandler Healthcare Conference. Additionally, Lumos will participate in a panel discussion at the Evercore ISI HealthCONx on December 3, where further one-on-one meetings will occur. The discussions will focus on Lumos' lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency, which is an orally administered alternative to injections.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
